Introduction
============

Normal-tension glaucoma (NTG) refers to a glaucomatous optic nerve head change and corresponding glaucomatous visual field defects without elevated intraocular pressure (IOP). A long-term collaborative study conducted in North America and Europe revealed that a 30% reduction in IOP exerted positive effects on the progression of visual field loss in NTG ([@b13-co-1-217]). Treatment goals for open-angle glaucoma have focused almost exclusively on lowering IOP using drugs, laser therapy or surgery. However, many investigators believe that IOP is not the only factor causally related to glaucomatous optic nerve changes and that some factors unrelated to IOP play significant roles in at least some NTG cases. Patients with glaucoma in whom IOP is lowered to within normal range often continue to suffer further progressive damage ([@b50-co-1-217]; [@b59-co-1-217]). A recent 10-year follow-up study showed a direct correlation between IOP levels and stabilization of the optic disc and visual field ([@b4-co-1-217]). Still, 10% of patients in that study with a mean final IOP of 13 mmHg continued to show disease progression.

The association of glaucoma with various systemic vascular diseases including low systemic blood pressure, transient nocturnal decreases in blood pressure, hypertension, migraine, vasospasm and diabetes has been reported ([@b23-co-1-217]; [@b33-co-1-217]; [@b6-co-1-217]; [@b20-co-1-217]). Many patients with chronic open-angle glaucoma present with coexisting vascular disorders, the most common of which is systemic hypertension, which occurs in 48% of the total chronic open-angle glaucoma population ([@b30-co-1-217]). Pharmacological treatment of non-IOP-dependent mechanisms in glaucoma has largely been limited to the use of calcium-channel blockers, which are widely used in the treatment of systemic hypertension, coronary artery diseases, stroke and arrhythmias. The jury is still out on the contrasting results for systemic calcium-channel blockers used on human glaucoma patients. Calcium-channel blockers may increase blood flow to the optic nerve head ([@b77-co-1-217]) and might be particularly useful in patients with NTG ([@b58-co-1-217]; [@b42-co-1-217]). However, one study showed no significant difference in progression of glaucoma in patients using or not using systemic calcium-channel blockers ([@b46-co-1-217]). Systemic calcium channel blockers can also have adverse cardiac effects, particularly if the patient is being treated with topical β-blockers ([@b42-co-1-217]).

Neuroprotection refers to the post-injury protection of neurons that were initially undamaged or only marginally damaged by a particular insult, but are at risk from toxic stimuli released by damaged cells, causing secondary degeneration ([@b84-co-1-217]). Secondary degeneration refers to the spread of degeneration to apparently healthy neurons that escape the primary insult, but are adjacent to injured neurons and thus exposed to the degenerative milieu that results ([@b84-co-1-217]).

Renin-angiotensin system
========================

The renin-angiotensin system (RAS) plays an important role in vasoconstriction, regulation of electrolyte balance and vascular remodeling. Local renin-angiotensin regulation is present in the eye ([@b19-co-1-217]; [@b79-co-1-217]). Since the initial application of angiotensin-converting enzyme (ACE) inhibitors as therapeutic agents for the treatment of hypertension, several additional clinical indications have been identified and approved ([@b9-co-1-217]). ACE inhibitor activity reportedly improves endothelial function and stimulates vascular remodeling, in addition to attenuating progression of arteriosclerosis and the occurrence of cardiovascular events in humans ([@b48-co-1-217]; [@b87-co-1-217]). The identification of ACE as a signaling molecule, which can be activated by the binding of ACE inhibitor, may account for some of the beneficial effects of this class of compounds on the cardiovascular system.

The RAS is an enzymatic cascade that generates a range of angiotensin peptides with varying biological actions. Definitive evidence that an RAS exists within the eye has been provided by molecular biological techniques such as real-time PCR and RNAse protection assays, which have revealed that components of the RAS are synthesized in ocular tissue. Renin is expressed in the pigmented epithelium and retinal Müller cells ([@b5-co-1-217]; [@b79-co-1-217]). Angiotensinogen is the sole precursor of angiotensin peptides and is cleaved to generate angiotensin I by renin and aspartyl proteases ([Figure 1](#f1-co-1-217){ref-type="fig"}). Angiotensin II can be liberated from angiotensin I by ACE or serine proteases. Angiotensin II is the main effector peptide of the RAS and acts on two main receptor subtypes: angiotensin type I (AT1); and angiotensin type II (AT2). Gene expression for AT1 and AT2 receptors has been identified in several ocular tissues, including the retina ([@b7-co-1-217]; [@b57-co-1-217]; [@b80-co-1-217]; [@b68-co-1-217]). AT1 receptors have been localized to the ganglion cell layer and inner nuclear layer in rat retina ([@b80-co-1-217]). AT1 receptor elicits most of the known physiological actions of angiotensin II, including vasoconstriction, electrolyte homeostasis, modulation of drinking behavior and stimulation of pituitary hormone release ([@b18-co-1-217]; [@b40-co-1-217]; [@b1-co-1-217]). In tissue pathology such as cardiovascular disease, nephropathies, liver cirrhosis and cancer, AT1 receptor is implicated in a wide variety of cell events including cell growth, differentiation and migration, fibrosis and inflammation and angiogenesis ([@b86-co-1-217]; [@b85-co-1-217]; [@b8-co-1-217]; [@b27-co-1-217]; [@b56-co-1-217]). Actions of the AT2 receptor are less well defined, but possibly oppose actions of the AT1 receptor, including vasodilation and apoptosis ([@b12-co-1-217]). However, evidence in a number of tissues suggests that the AT2 receptor displays similar actions to the AT1 receptor, promoting cell growth and angiogenesis ([@b45-co-1-217]; [@b10-co-1-217]; [@b68-co-1-217]).

The kallikrein-kinin system
===========================

In general, the kallikrein-kinin system is thought to counterbalance the activities of the RAS. Kinin peptides are generated from kininogens by kallikrein, a serine protease ([Figure 1](#f1-co-1-217){ref-type="fig"}). The actions of kinin peptides include promoting inflammation, leakage of plasma proteins, pain and more recently, angiogenesis.

Components of the kallikrein-kinin system have been identified in the eye. Kallikrein and kininase II activity are found in the retina, choroid and ciliary body of swine eyes, with the highest activity of kininase I in aqueous humor ([@b39-co-1-217]). Bradykinin is a vasodilating nonapeptide that is degraded by ACE ([@b38-co-1-217]). Plasma bradykinin levels are increased in patients treated with ACE inhibitor ([@b17-co-1-217]). Bradykinin displays a wide range of actions, mediated through at least two subtypes of receptor: B~1~ and B~2~ ([@b67-co-1-217]). B~1~ receptor has been implicated in angiogenesis, as bradykinin stimulates endothelial cell proliferation in vitro via activation of the B~1~ receptor cAMP pathway ([@b55-co-1-217]). Most biological actions are mediated by B~2~ receptors. Bradykinin-B~2~ receptors are reportedly abundantly distributed in vascular tissues and smooth muscles cell, and also in human brain ([@b65-co-1-217]) and retinal ([@b48-co-1-217]) neurons. In human retina, tissue kallikrein, low molecular weight kininogen and B~1~ and B~2~ receptors are expressed in neuronal cells of the outer nuclear layer, inner nuclear layer and ganglion cell layer, and on the retinal vasculature ([@b48-co-1-217]). In addition, mRNA for the B~2~ receptor has been identified in the retinal ganglion cell layer and in a population of cells adjacent to the sclerocorneal junction in rats ([@b75-co-1-217]). In B~2~ receptor-deficient mice with hindlimb ischemia, ACE inhibition increased vessel density and capillary number in the ischemic leg ([@b71-co-1-217]). This was not observed in the ischemic hindlimb of mice lacking B~2~ receptor ([@b71-co-1-217]).

Blood flow
==========

AT1 receptor antagonist ameliorates impaired optic nerve head blood flow in rabbits ([@b41-co-1-217]). The decreased flow velocity in hypertensive patients improved with an oral ACE inhibitor ([@b72-co-1-217]). ACE inhibitor may act in several ways to increase the blood flow in the eye. The L-arginine nitric oxide pathway is an important local regulator of vascular tone. In the ophthalmic circulation, bradykinin is a potent activator of this pathway, and it causes pronounced endothelium-dependent relaxations in isolated blood vessels ([@b82-co-1-217]; [@b31-co-1-217], [@b32-co-1-217]), which releases nitric oxide through B~2~ receptors ([@b52-co-1-217]), and increases in ophthalmic flow in the isolated perfused eye ([@b51-co-1-217]). Stimulation of the L-arginin nitric oxide pathway by bradykinin not only leads vasodilation but also to the inhibition of migration ([@b60-co-1-217]) and proliferation of vascular smooth muscle cells ([@b26-co-1-217]; [@b21-co-1-217]).

It must be emphasized that angiotensin II is also assumed to play a role in cerebral myogenic autoregulation ([@b73-co-1-217]). Myogenic autoregulation may also be present in the choroidal vasculature ([@b43-co-1-217]). Hence angiotensin receptor blockade may be useful to prevent abnormal cerebral and ocular autoregulation in patients with activated RAS.

ACE inhibitors and diabetic retinopathy
=======================================

Diabetic retinopathy is a major cause of blindness in those of working age ([@b29-co-1-217]). Diabetic retinopathy progresses from a mild non-proliferative form characterized by vascular permeability to moderate or severe non-proliferative diabetic retinopathy in which retinal vessels close, and finally to proliferative diabetic retinopathy that comprises new blood vessel growth typically between the retina and posterior surface of the vitreous.

Angiotensin II is a known stimulus for the expression of vascular endothelial growth factor (VEGF), which is associated with the induction of retinal neovascularization ([@b2-co-1-217]; [@b28-co-1-217]; [@b63-co-1-217]; [@b62-co-1-217]). Vitreous levels of both angiotensin II and VEGF are significantly higher in eyes with active proliferative diabetic retinopathy (PDR) than in eyes with quiescent PDR, suggesting that upregulated angiotensin II may be involved in the progression of neovascularization ([@b25-co-1-217]). In experimental diabetic models, inhibition of angiotensin II formation with ACE inhibition results in suppression of VEGF expression ([@b54-co-1-217]; [@b34-co-1-217]). Vitreous VEGF levels were higher in patients with PDR than in patients without diabetes, but these high levels were significantly reduced after ACE inhibitor treatment ([@b37-co-1-217]). A growing number of both clinical and experimental studies suggest that inhibition of the RAS can provide protective effects against diabetic retinopathy in the absence of hypertension. The most widely cited clinical evidence for a role of the RAS in diabetic retinopathy in the absence of hypertension was produced in the EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetic Mellitus study (EUCLID), which reported that ACE inhibition with lisinopril reduced progression of retinopathy in type I diabetic patients who were normotensive ([@b11-co-1-217]). This 2-year multicenter study showed that progression of retinopathy was reduced by at least one level in the lisinopril-treated group compared with that in placebo-treated control individuals after adjustment for center. This study also showed a decreased rate of progression to PDR in the lisinopril-treated group after adjustment for glycemic control. At 1 month, mean diastolic blood pressure was 74 mmHg for the lisinopril-treated group and 77 mmHg in the placebo group and this difference was maintained over the course of study ([@b76-co-1-217]). The normotensive Appropriate Blood Pressure Control in Diabetes (ABCD) study compared the effects on progression of diabetic retinopathy obtained with moderate and intensive control of blood pressure in normotensive type 2 diabetic patients treated with enalapril or nisoldipine ([@b70-co-1-217]). Follow-up blood pressure was 128 mmHg for the intensive treatment group and 137 mmHg for the moderate control group. At 5 years, this prospective study showed that progression of diabetic retinopathy was 34% in the intensively treated group, compared with 46% in the moderately treated group. No significant difference in response was seen between enalapril- and nisoldipine-treated patients. These results showed that a decrease in blood pressure in normotensive patients with type 2 diabetes was associated with reductions in progression of diabetic retinopathy. The results of both the EUCLID and normotensive ABCD studies show significant beneficial effects of ACE inhibition on progress of diabetic retinopathy in diabetic patients in the absence of hypertension, but the mechanisms that contribute to this response have yet to be identified. Both studies reported a significant reduction in systemic blood pressure. These results may suggest that reduction of blood pressure within the normotensive range could contribute to the decreases in progression of diabetic retinopathy. However, inhibition of the RAS has also been shown to effect a number of circulating factors, including reactive oxygen species and inflammatory cytokines, which could indirectly contribute to vascular effects ([@b44-co-1-217]). In addition, mechanical stretch can activate the AT1 receptor ([@b88-co-1-217]) and upregulate the VEGF pathway in retinal endothelial cells ([@b74-co-1-217]), suggesting that blood pressure itself may affect actions of the AT1 receptor. The relative contributions of reduced systemic blood pressure within the normotensive range and other systemic or local ocular effects of RAS inhibitors to the progression of diabetic retinopathy remain unknown.

Potential use of ACE inhibitors in glaucoma treatment
=====================================================

Elevated IOP is the most important risk factor for glaucomatous damage, but it is still only a risk factor. Visual damage in glaucoma results from a combination of elevated IOP and IOP-independent risk factors. Although hypothesizing that NTG has an underlying mechanism independent of IOP is tempting, use of hypotensive treatment strategies does appear to slow the progression of NTG ([@b13-co-1-217]). However, the findings of the Collaborative Normal Tension Glaucoma Study Group showed no significant association between mean IOP change and visual field progression ([@b13-co-1-217]; [@b14-co-1-217]).

Even more recently, application of neuroprotection to the treatment of non-IOP-dependent glaucomatous damage has received increasingly intensive attention. If glaucoma is actually a collection of diseases that all result in a common optic neuropathy, therapy aimed at preventing the process of damage would show enormous therapeutic potential.

ACE inhibitors have recently attracted attention as a new class of drugs for the treatment of glaucoma. ACE inhibitors have been shown to lower IOP in patients with ocular hypertension or primary open-angle glaucoma ([@b15-co-1-217]). Lotti and Pawlowski ([@b47-co-1-217]) proposed the involvement of prostaglandins in the ocular hypotensive effect of enalaprilat. This conclusion was based on the finding that indomethacin blocked the IOP-lowering effect of enalaprilat. ACE inhibitors are also inhibitors of kininase II and thus prevent the breakdown of bradykinin. Increased bradykinin levels promote prostaglandin synthesis. Prostaglandin, particularly PGF~2α~, is known to increase uveoscleral outflow of aqueous humor ([@b16-co-1-217]).

Apoptosis has been shown to be at least one of the mechanisms for retinal ganglion cell death in monkey models of pressure-induced glaucoma ([@b64-co-1-217]). Evidence for apoptosis in Alzheimer's disease has been provided from both animal models and human materials ([@b69-co-1-217]). Longitudinal intervention studies for hypertension, such as the Systolic Hypertension in Europe (SYST-EUR) study and the Peridopril Protection Against Recurrent Stroke Study (PROGRESS) trial, have reported a significant inverse relationship between antihypertensive treatments and risk of vascular-related dementia ([@b24-co-1-217]; [@b78-co-1-217]). For example, SYST-EUR data from the 8-year follow-up phase of the program have suggested a 55% reduction in risk for dementia during long-term active treatment with the ACE inhibitor enalapril ([@b24-co-1-217]). Similarly, the PROGRESS study indicated that a substantially reduced risk for dementia (34%) was confirmed by treatment with the ACE inhibitor perindopril. Long-term use of ACE inhibitors may have a protective role against the development of Alzheimer's disease ([@b61-co-1-217]).

Bradykinin has a protective action against glutamate neurotoxicity through bradykinin-B~2~ receptors in cultured retinal neurons (Yasuyoshi et al 2004). We have previously reported that NTG patients were more sensitive to exogenous bradykinin than normal subjects ([@b35-co-1-217]). These data suggest that endogenous bradykinin levels may be lower in NTG patients than in normal subjects. Angiotensin I-converting enzyme and endothelial cell kininase are thought to represent one and the same enzyme ([@b53-co-1-217]). As a kininase, this enzyme is responsible for the degradation of bradykinin. ACE inhibitors are thus capable of prolonging the half-life of any bradykinin in the proximity of endothelium. Long-term treatment with ACE inhibitors increases plasma bradykinin levels ([@b17-co-1-217]). [@b83-co-1-217] recently reported that bradykinin has protective effects on neurotoxicity induced by glutamate through bradykinin B~2~ receptors in cultured retinal neurons. The protective action of bradykinin is mediated by the opening of the mitochondrial adenosine triphosphate-sensitive potassium channel ([@b81-co-1-217]).

Inhibition of bradykinin degradation by ACE inhibitors may increase the activity of superoxide dismutase and modulate the production of nitric oxide, leading to the inactivation of reactive oxygen species, while also inhibiting various pro-oxidative mechanisms within the vasculature ([@b22-co-1-217]). Lower angiotensin II levels, such as seen during treatment with ACE inhibitor, may have beneficial effects on outcome by lowering vascular superoxide anion production ([@b66-co-1-217]). ACE inhibitor may benefit vascular function. A previous study reported average rates of decline in NTG as −0.41 dB per year ([@b3-co-1-217]) with a mean follow-up of 4.5 years. In subjects with a significant decline, mean rate of loss across the entire field was −0.90 dB/year ([@b3-co-1-217]). In subjects who had not progressed, mean rate of loss across the entire field was −0.14 dB/year ([@b3-co-1-217]). We retrospectively reviewed a total of 38 patients with NTG ([@b36-co-1-217]), divided into 3 groups: control subjects with no previous history of hypertension; NTG hypertension patients receiving ACE inhibitor; and NTG hypertension patients receiving other antihypertensive drug treatment. In the ACE inhibitor-treated group, mean deviation (MD) change per year was 0.48 ± 0.19 dB, compared to −0.38 ± 0.23 dB in control subjects, and −0.50 ± 0.39 dB in the other antihypertensive drug-treated group. These results suggest that ACE inhibitors might exert favorable effects on the visual field in patients with NTG ([@b36-co-1-217]). ACE inhibitors have numerous properties that theoretically should be beneficial in treating non-IOP-dependent mechanisms in glaucoma.

Randomized, controlled clinical trials have not been performed to clarify neuroprotective effects of ACE inhibitors in glaucoma yet. In the absence of such trials, further studies in various animal models of glaucoma are also needed.
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